We are live on ! Find out more
IBT

International Biotechnology Trust Portfolio holdings

AUM $297M
1-Year Est. Return 17.25%
This Fund
S&P 500
This Quarter Est. Return
-8.33%
1 Year Est. Return
+17.25%
3 Year Est. Return
+11.14%
5 Year Est. Return
+79.35%
10 Year Est. Return
–
AUM
$219M
AUM Growth
-$58.2M
Cap. Flow
-$26.3M
Cap. Flow %
-11.97%
Top 10 Hldgs %
60.72%
Holding
71
New
8
Increased
9
Reduced
20
Closed
15

Top Buys

Rank Stock Value
1
ZGNX
Zogenix, Inc.
ZGNX
+$8.71M
2
CCXI
ChemoCentryx, Inc.
CCXI
+$8.07M
3
PTCT icon
PTC Therapeutics
PTCT
+$7.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$5.64M
5
LLY icon
Eli Lilly
LLY
+$2.75M

Top Sells

Rank Stock Value
1
REGN icon
Regeneron Pharmaceuticals
REGN
+$10.8M
2
STML
Stemline Therapeutics, Inc.
STML
+$10.3M
3
ILMN icon
Illumina
ILMN
+$8.32M
4
GILD icon
Gilead Sciences
GILD
+$3.87M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$3.58M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BLUE
51
DELISTED
bluebird bio
BLUE
$505K 0.23%
849
-463
-35% -$451K
GBT
52
DELISTED
Global Blood Therapeutics, Inc.
GBT
$498K 0.23%
9,800
-13,300
-58% -$891K
ITCI
53
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$352K 0.16%
+23,000
New +$500K
ESPR
54
DELISTED
Esperion Therapeutics
ESPR
$298K 0.14%
9,500
-20,500
-68% -$1.08M
ZEAL
55
DELISTED
Zealand Pharma A/S American Depositary Shares
ZEAL
$183K 0.08%
5,653
– –
ANAB icon
56
AnaptysBio
ANAB
$1.7B
$140K 0.06%
10,000
– –
GMED icon
57
Globus Medical
GMED
$11.1B
– –
-24,200
Closed -$1.43M
IFRX icon
58
InflaRx
IFRX
$335M
– –
-220,000
Closed -$869K
ILMN icon
59
Illumina
ILMN
$34.4B
– –
-25,803
Closed -$8.32M
MYGN icon
60
Myriad Genetics
MYGN
$304M
– –
-25,000
Closed -$680K
NVCR icon
61
NovoCure
NVCR
$2.09B
– –
-35,500
Closed -$2.99M
REGN icon
62
Regeneron Pharmaceuticals
REGN
$83.2B
– –
-28,830
Closed -$10.8M
SGMO
63
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-303,000
Closed -$2.53M
SUPN icon
64
Supernus Pharmaceuticals
SUPN
$2.57B
– –
-19,953
Closed -$473K
ONC
65
BeOne Medicines Ltd
ONC
$42.1B
– –
-14,000
Closed -$2.32M
GTHX
66
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
– –
-11,200
Closed -$296K
MOR
67
DELISTED
MorphoSys AG American Depositary Shares
MOR
– –
-11,295
Closed -$402K
RDUS
68
DELISTED
Radius Health, Inc.
RDUS
– –
-17,000
Closed -$342K
AKCA
69
DELISTED
Akcea Therapeutics Inc
AKCA
– –
-31,723
Closed -$536K
STML
70
DELISTED
Stemline Therapeutics, Inc.
STML
– –
-965,245
Closed -$10.3M
DERM
71
DELISTED
Dermira, Inc.
DERM
– –
-30,000
Closed -$454K
1 2
3

Similar funds

DCMIC
Decheng Capital Management III (Cayman) Grand Cayman, Cayman Islands $300M AUM 15.74% 1-Year Est. Return
DT
Daniels + Tansey Wilmington, Delaware $289M AUM 18.06% 1-Year Est. Return
3LCM
3D/L Capital Management Hartford, Connecticut $308M AUM 13.67% 1-Year Est. Return
TFA
Triad Financial Advisors Greensboro, North Carolina $284M AUM 14.95% 1-Year Est. Return
SFG
Steward Financial Group Colleyville, Texas $315M AUM 13.78% 1-Year Est. Return
AEPLI
AH Equity Partners LSV I Menlo Park, California $315M AUM 9.31% 1-Year Est. Return
CC
Chanos & Company New York $318M AUM 4.62% 1-Year Est. Return
BC
Brahman Capital New York $275M AUM 18.08% 1-Year Est. Return

International Biotechnology Trust's Q1 2020 Portfolio in Review

As of Q1 2020, International Biotechnology Trust held 71 positions worth $219M, down 21% from $278M the previous quarter. Its ten largest holdings account for 61% of the portfolio.

International Biotechnology Trust withdrew a net $26.3M in Q1 2020, closing 15 positions and reducing 20 holdings. Its most notable exit was Regeneron Pharmaceuticals, an estimated $10.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, International Biotechnology Trust opened a new position in ChemoCentryx, Inc. worth $7.63M.

  • International Biotechnology Trust's largest Q1 2020 buy was ChemoCentryx, Inc.: 190,000 shares worth $7.63M.
  • International Biotechnology Trust added most to Zogenix, Inc. in Q1 2020, an estimated $8.71M increase.
  • International Biotechnology Trust's biggest Q1 2020 reduction was Gilead Sciences, cutting an estimated $3.87M.
  • International Biotechnology Trust fully exited Regeneron Pharmaceuticals in Q1 2020, selling an estimated $10.8M.
  • International Biotechnology Trust's ten largest holdings make up 61% of its $219M portfolio in Q1 2020.
  • International Biotechnology Trust opened 8 new positions and closed 15 in Q1 2020.
  • International Biotechnology Trust's portfolio value fell 21% quarter-over-quarter to $219M.

Based on International Biotechnology Trust's 13F filing for Q1 2020, filed 18 May 2020.